A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects

Sponsor
Novo Nordisk A/S
Study ID
NCT03010475
Phase
PHASE1
Status
Completed

Conditions

  • Diabetes
  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Furosemide — DRUG
    Oral administration A total of three single doses.
  • Rosuvastatin — DRUG
    Oral administration. A total of three single doses.
  • SNAC — DRUG
    Oral administration. A total of five single doses.
  • Semaglutide — DRUG
    Oral administration. Once daily.

Study Details

This trial is conducted in Europe. Tha aim of this trial is to investigate the effect of oral semaglutide on the pharmacokinetics of furosemide and rosuvastatin in healthy subjects.

Key Dates

Start date
Jan 5, 2017
Status verified
Dec 2017
Primary completion
Jun 4, 2017
Completion
Aug 9, 2017

Study Design

Enrollment
41 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Furosemide/Rosuvastatin/SNAC/Semaglutide

Primary Outcome Measure

Area under the furosemide plasma concentration-time curve [ Time Frame: day 1, day 7, day 54 ]

Related Studies